|
|
|
|
| LEADER |
00000cam a2200000xi 4500 |
| 001 |
b11391898 |
| 003 |
CoU |
| 005 |
20200807175939.7 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
200622t20202020maua ob 000 0 eng d |
| 020 |
|
|
|a 9780128211199
|q electronic book
|
| 020 |
|
|
|a 0128211199
|q electronic book
|
| 020 |
|
|
|z 9780128211182
|
| 020 |
|
|
|z 0128211180
|
| 035 |
|
|
|a (OCoLC)scd1159211098
|
| 035 |
|
|
|a (OCoLC)1159211098
|
| 037 |
|
|
|a scd00747742/153
|
| 040 |
|
|
|a YDX
|b eng
|e rda
|c YDX
|d OPELS
|d EBLCP
|d OCLCF
|d YDXIT
|d OCLCO
|d UKMGB
|
| 049 |
|
|
|a GWRE
|
| 050 |
|
4 |
|a RM331
|b .P53 2020
|
| 245 |
0 |
0 |
|a Placebo effects in neurologic disease /
|c edited by Natalie P. Witek, Christopher G. Goetz, Glenn T. Stebbins.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2020.
|
| 264 |
|
4 |
|c ©2020.
|
| 300 |
|
|
|a 1 online resource (xii, 266 pages) :
|b color illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 153.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
8 |
|
|a Intro -- Placebo Effects in Neurologic Disease -- Copyright -- Contents -- Contributors -- Preface -- Part 1: Background and methods in placebo -- Chapter One: Better than nothing: A historical account of placebos and placebo effects from modern to contemporary medicine -- 1. Introduction -- 2. The etymology of ̀̀placebo ́́and its first recorded use in medicine (fourth century-1772) -- 3. Placebos as treatments in clinical practice (1772-1954) -- 4. Placebos as controls in scientific research (1772-1930s) -- 5. The ̀̀Conferences on Therapy ́́at Cornell University (1930s-1946)
|
| 505 |
8 |
|
|a 6. Beecher and the ̀̀powerful placebo ́́(1955) -- 7. The rise of RCTs and the first pioneering studies on placebo effects (1955-1970s) -- 8. The empirical study of placebo effects and the golden age of placebo research (1970s-) -- 9. Summary and conclusions -- Acknowledgment -- References -- Chapter Two: Determinants of placebo effects -- 1. Introduction -- 2. Intrinsic factors impacting placebo response -- 2.1. Neural systems involved in the placebo response -- 2.2. Patient-based determinants -- 2.2.1. Personality factors -- 2.2.2. Genetic factors -- 2.2.3. Environmental factors.
|
| 505 |
8 |
|
|a 2.3. Clinician/researcher based determinants -- 2.3.1. Personality factors -- 2.3.2. Environmental factors -- 3. Extrinsic factors impacting placebo response -- 3.1. Study design -- 3.2. Advertising, branding, and exclusivity as enhancers of placebo effects -- 4. Culture -- 5. Future directions -- References -- Chapter Three: Strategies to minimize placebo effects in research investigations -- 1. Introduction -- 2. Concepts and definitions -- 3. Why may the placebo effect be detrimental in clinical trials? -- 4. The impact -- 5. Placebo effect in neurology.
|
| 505 |
8 |
|
|a 6. Strategies to minimize the placebo effect in clinical trials -- 6.1. Study design -- 6.2. Statistical power -- 6.3. Patient selection -- 6.4. Allocation stratification -- 6.5. Outcomes and endpoints -- 6.6. Analysis -- 7. Challenges and future direction -- References -- Chapter Four: Maximizing placebo response in neurological clinical practice -- 1. Introduction -- 2. Why should placebo be maximized in the clinic? -- 3. How should placebo be maximized in the clinic? -- 3.1. Personalizing placebo response and utilizing predictors of placebo response.
|
| 505 |
8 |
|
|a 3.2. Strategies that modulate expectations -- 3.3. Impact of learning -- 4. Future perspectives -- Funding -- Conflict of interest -- References -- Chapter Five: Statistical methods in handling placebo effect -- 1. Introduction -- 2. Trial designs -- 2.1. Designs to eliminate and/or reduce placebo response -- 2.2. Crossover study design -- 2.3. Placebo run-in and randomized withdrawal designs -- 2.4. Sequential parallel comparison design (SPCD) -- 2.5. Two-way enriched design (TED) -- 2.6. Designs to estimate placebo response -- 2.6.1. Delayed-start or randomized-start designs.
|
| 588 |
|
|
|a Description based on online resource; title from digital title page (viewed on July 15, 2020)
|
| 650 |
|
0 |
|a Placebos (Medicine)
|0 http://id.loc.gov/authorities/subjects/sh85102563.
|
| 650 |
|
0 |
|a Central nervous system
|x Diseases.
|0 http://id.loc.gov/authorities/subjects/sh85021909.
|
| 650 |
|
7 |
|a Central nervous system
|x Diseases.
|2 fast
|0 (OCoLC)fst00850732.
|
| 650 |
|
7 |
|a Placebos (Medicine)
|2 fast
|0 (OCoLC)fst01732316.
|
| 700 |
1 |
|
|a Witek, Natalie P.,
|e editor.
|
| 700 |
1 |
|
|a Goetz, Christopher G.,
|e editor.
|0 http://id.loc.gov/authorities/names/n81012832
|1 http://isni.org/isni/0000000063047958.
|
| 700 |
1 |
|
|a Stebbins, Glenn T.,
|e editor.
|
| 776 |
0 |
8 |
|c Original
|z 0128211180
|z 9780128211182
|w (OCoLC)1135669342.
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 153.
|0 http://id.loc.gov/authorities/names/no96060758.
|
| 856 |
4 |
0 |
|u https://colorado.idm.oclc.org/login?url=https://www.sciencedirect.com/science/bookseries/00747742/153
|z Full Text (via ScienceDirect)
|
| 907 |
|
|
|a .b113918987
|b 09-01-20
|c 08-11-20
|
| 998 |
|
|
|a web
|b 08-31-20
|c b
|d b
|e -
|f eng
|g mau
|h 0
|i 1
|
| 907 |
|
|
|a .b113918987
|b 08-31-20
|c 08-11-20
|
| 944 |
|
|
|a MARS - RDA ENRICHED
|
| 915 |
|
|
|a I
|
| 956 |
|
|
|a ScienceDirect ebooks
|
| 956 |
|
|
|b ScienceDirect All Books
|
| 999 |
f |
f |
|i f76ad121-f7cd-5bed-97dd-075534a9fc33
|s 536a534c-66d0-5ac8-bf60-fe2ebc8b55b1
|
| 952 |
f |
f |
|p Can circulate
|a University of Colorado Boulder
|b Online
|c Online
|d Online
|e RM331 .P53 2020
|h Library of Congress classification
|i web
|n 1
|
